The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine (Q44071057)

29 November 2017

title

The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine (English)

1 reference

29 November 2017

1 reference

1 reference

Hubert G.M. Niesters

Hubert G M Niesters

3

1 reference

29 November 2017

Bettina E. Hansen

Bettina E Hansen

2

1 reference

29 November 2017

author name string

Leonieke M.M. Wolters

1

1 reference

29 November 2017

Rachel S. Levi-Drummer

4

1 reference

29 November 2017

Avidan U. Neumann

5

1 reference

29 November 2017

Solko W. Schalm

6

1 reference

29 November 2017

Robert A. de Man

7

1 reference

29 November 2017

publication date

1 August 2002

1 reference

29 November 2017

August 2002

0 references

published in

Journal of Hepatology

1 reference

29 November 2017

volume

37

1 reference

29 November 2017

issue

2

1 reference

29 November 2017

page(s)

253-258

1 reference

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Viral dynamics in chronic hepatitis B patients during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

Clinical pharmacokinetics of lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900113-7

7 January 2021

10.1016/S0168-8278(02)00113-7

Identifiers

DOI

0 references

1 reference